All Releases
 |
Avalon Pharmaceuticals Receives Extension of Time to Comply with NASDAQ Deficiency Notice
Dec 22, 2008
|
11.2 KB |
|
| |
GERMANTOWN, Md., Dec 22, 2008 (BUSINESS WIRE) -- Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX), today announced that on
December 18, 2008, it received a letter from The NASDAQ Stock Market,
LLC notifying the Company that it had been granted an extension of time
for compliance with NASDAQ Marketplace Rule 4450(a)(3). The Compan...
|
|
Avalon Pharmaceuticals Receives NASDAQ Deficiency Notice
Nov 25, 2008
|
7.8 KB |
|
| |
GERMANTOWN, Md., Nov 25, 2008 (BUSINESS WIRE) -- Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that on
November 20, 2008 it received a Deficiency Notice from The NASDAQ Stock
Market, LLC notifying the Company that it is not in compliance with
NASDAQ Marketplace Rule 4450(a)(3) because the Company's stockholders...
|
|
Clinical Data, Inc. to Acquire Avalon Pharmaceuticals
Oct 28, 2008
|
15.9 KB |
|
| |
NEWTON, Mass. & GERMANTOWN, Md., Oct 28, 2008 (BUSINESS WIRE) -- Clinical Data, Inc. (NASDAQ: CLDA) and Avalon Pharmaceuticals, Inc. (NASDAQ: AVRX) today announced that they have entered into a definitive merger agreement for Clinical Data to acquire Avalon in an all-stock transaction valued at approximately $10 million. The combined company will h...
|
|
Avalon Pharmaceuticals Receives Nasdaq Deficiency Notice
Sep 26, 2008
|
7.9 KB |
|
| |
GERMANTOWN, Md., Sep 26, 2008 (BUSINESS WIRE) -- Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that on September 24, 2008 it received a Deficiency Notice from The NASDAQ Stock Market, LLC notifying the Company that it is not in compliance with NASDAQ Marketplace Rule 4450(a)(5)because the Company's common stock failed to close above t...
|
|
Avalon Pharmaceuticals Reports Second Quarter 2008 Results
Aug 13, 2008
|
14.9 KB |
|
| |
GERMANTOWN, Md., Aug 13, 2008 (BUSINESS WIRE) -- Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapeutics, today announced financial and operational results for the second quarter of 2008. For the three months ended June 30, 2008, net loss was $5.6 m...
|
|
Avalon Pharmaceuticals Sets Second Quarter 2008 Conference Call Date
Aug 5, 2008
|
7.8 KB |
|
| |
GERMANTOWN, Md., Aug 05, 2008 (BUSINESS WIRE) -- Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that it is scheduled to release financial results for the second quarter of 2008 on Wednesday, August 13, 2008, at approximately 10:00 am Eastern Time. The Company will host a conference call later that day at 1:00 pm Eastern Time to provide...
|
|
Avalon Pharmaceuticals Nominates Lead Clinical Development Candidate in its Beta-catenin Pathway Inhibitor Program
Jun 26, 2008
|
10.0 KB |
|
| |
GERMANTOWN, Md., Jun 26, 2008 (BUSINESS WIRE) -- Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), announced today the nomination of AVN316 as a lead clinical development candidate in its Beta-catenin Pathway Inhibitor program. This novel compound inhibits the Beta-catenin pathway and is a potent inducer of cancer cell death. The Company plans to begin c...
|
|
Avalon Pharmaceuticals Reports First Quarter 2008 Results
May 7, 2008
|
13.5 KB |
|
| |
GERMANTOWN, Md., May 07, 2008 (BUSINESS WIRE) -- Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapeutics, today announced financial and operational results for the first quarter of 2008. For the three months ended March 31, 2008, net loss was $6.2 m...
|
|
Avalon Pharmaceuticals to Release First Quarter 2008 Results
Apr 30, 2008
|
8.2 KB |
|
| |
GERMANTOWN, Md., Apr 30, 2008 (BUSINESS WIRE) -- Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that it is scheduled to release financial results for the first quarter of 2008 on Wednesday, May 7, 2008 after the close of the U.S. financial markets. The Company will also host a conference call on Thursday, May 8, 2008 at 8:30 am Eastern...
|
|
Avalon Pharmaceuticals Identifies Small Molecule Inhibitors of the Aurora/Centrosome Cancer Pathway that Block PLK3 Protein Function
Apr 14, 2008
|
9.1 KB |
|
| |
GERMANTOWN, Md., Apr 14, 2008 (BUSINESS WIRE) -- Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX), announced today that it has used AvalonRx(R), its biomarker based drug discovery system, to identify small molecule inhibitors of the Aurora/Centrosome pathway, and to reveal the protein targeted by these compounds. Their findings were announced today in a...
|
|
Avalon Pharmaceuticals to Present at the American Association for Cancer Research 2008 Annual Meeting
Apr 7, 2008
|
9.1 KB |
|
| |
GERMANTOWN, Md., Apr 07, 2008 (BUSINESS WIRE) -- Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that it will conduct four poster presentations at the American Association for Cancer Research 2008 Annual Meeting, April 12-16, in San Diego, CA.
Abstract #2306, "Identification of Small Molecule Inhibitors of the Aurora/Centrosome Path...
|
|
Avalon Pharmaceuticals Receives Audit Opinion Containing Going Concern Statement
Apr 4, 2008
|
7.7 KB |
|
| |
GERMANTOWN, Md., Apr 04, 2008 (BUSINESS WIRE) -- Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced, in compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), that the independent audit report included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007 contained an unqualified audit opinion from its ind...
|
|
Avalon Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Mar 19, 2008
|
15.6 KB |
|
| |
GERMANTOWN, Md., Mar 19, 2008 (BUSINESS WIRE) -- Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapeutics, today announced financial and operational results for the fourth quarter and full year of 2007. For the three months ended December 31, 2007, n...
|
|
Avalon Pharmaceuticals Appoints Philip Frost, M.D., Ph.D., to Its Board of Directors
Mar 17, 2008
|
8.2 KB |
|
| |
GERMANTOWN, Md.--(BUSINESS WIRE)--March 17, 2008--Avalon
Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced the appointment
of Philip Frost, M.D., Ph.D., to its Board of Directors effective
March 14, 2008. The addition of Dr. Frost brings the Avalon Board to
eight members.
"We are pleased to have Dr. Frost join the Avalon B...
|
|
Avalon Pharmaceuticals to Release Fourth Quarter and Full Year 2007 Results
Mar 12, 2008
|
7.4 KB |
|
| |
GERMANTOWN, Md.--(BUSINESS WIRE)--March 12, 2008--Avalon
Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that it is
scheduled to release financial results for the fourth quarter and full
year of 2007 on Wednesday, March 19, 2008 after the close of the U.S.
financial markets. The Company will also host a conference call on
Thursda...
|
|
Avalon Pharmaceuticals to Present at 20th Annual Roth Capital Partners Growth Stock Conference
Feb 14, 2008
|
7.3 KB |
|
| |
GERMANTOWN, Md., Feb 14, 2008 (BUSINESS WIRE) -- Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that
C. Eric Winzer, Executive Vice President and CFO, will provide an
update on the Company at the 20th Annual Roth Capital Partners Growth
Stock Conference.
The conference will be held at The Ritz Carlton in Laguna Niguel,
CA, Febr...
|
|
Avalon Pharmaceuticals to Present at BIO CEO & Investor Conference
Feb 6, 2008
|
7.6 KB |
|
| |
GERMANTOWN, Md.--(BUSINESS WIRE)--Feb. 6, 2008--Avalon
Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that Kenneth C.
Carter, Ph.D., President and CEO, will provide an update on the
Company at the BIO CEO & Investor Conference.
The conference will be held at the Waldorf-Astoria Hotel in New
York from February 11-13. Dr....
|
|
Avalon Pharmaceuticals Announces the Initiation of Compound Characterization Phase in Drug Discovery Collaboration
Jan 14, 2008
|
8.6 KB |
|
| |
GERMANTOWN, Md., Jan 14, 2008 (BUSINESS WIRE) -- Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX), today announced the
initiation of the next phase in its drug discovery collaboration with
Novartis. The collaboration aims to discover small molecule
therapeutic compounds targeted against a pathway selected by Novartis.
The terms of the collaboration ...
|
|
Avalon Pharmaceuticals Announces their Beta-catenin Inhibitors Demonstrate Potent Cytotoxic Effects in Multiple Myeloma
Dec 10, 2007
|
10.0 KB |
|
| |
GERMANTOWN, Md.--(BUSINESS WIRE)--Dec. 10, 2007--Avalon
Pharmaceuticals Inc. (Nasdaq: AVRX), yesterday presented results at
the American Society of Hematology (ASH) Annual Meeting on its
Beta-catenin pathway inhibitor program.
Results show this small molecule compound family has potent
inhibitory effects on Wnt/Beta-catenin s...
|
|
AVN944 Biomarkers Correlate with Clinical Effects and Disease Stabilization in Adult AML Patients
Dec 8, 2007
|
8.5 KB |
|
| |
GERMANTOWN, Md.--(BUSINESS WIRE)--Dec. 8, 2007--Avalon
Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced preliminary
results from its ongoing AVN944 Phase I trial in adult Acute
Myelogenous Leukemia (AML) patients at the American Society of
Hematology (ASH) Annual Meeting.
The research shows that AVN944 is well tolerated i...
|
|
|
